Some information on this page may be available only to Healthcare Professionals. Please

Novartis is reimagining medicine to improve and extend people’s lives. As a leading global medicines company, we use innovative science and digital technologies to create transformative treatments in areas of great medical need. In our quest to find new medicines, we consistently rank among the world’s top companies investing in research and development. Novartis products reach nearly 800 million people globally and we are finding innovative ways to expand access to our latest treatments. About 110,000 people of more than 140 nationalities work at Novartis around the world. To learn more about Novartis in Singapore, visit https://www.novartis.com.sg

Website: https://www.novartis.com.sg/

Facebook: https://www.facebook.com/novartis

Twitter: https://twitter.com/novartis

Youtube: https://www.youtube.com/channel/UCrOUkNI1eCMumFJ1PK6PaYw

Instagram: http://instagram.com/novartis

LinkedIn: https://www.linkedin.com/company/novartis-sg/

Media

Videos

Branches

1

Novartis

20 Pasir Panjang Road #10-25/28, Mapletree Business City (West Tower), Singapore 117439

Key Trials

8 trials shown

Novartis

Key trial

Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases

Study CDFV890G12101 is an open-label, phase 1b, multicenter study with a randomized two-dose optimization part, and a dose expansion part consisting of two groups evaluating DFV890

Study number:
NCT05552469
Cohorts:
1
Study phase:
1
Overall status:
Not yet recruiting
Study type:
Targeted therapy

Novartis

Key trial

Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

This is Phase Ib/II, multicenter, open-label adaptive platform study of JDQ443 with select therapies in patients with advanced solid tumors harboring the KRAS G12C mutation.

Study number:
NCT05358249
Cohorts:
3
Study phase:
1, 2
Overall status:
Recruiting
Study type:
Targeted therapy, Biomarker

Novartis

Key trial

PHE885 CAR-T Therapy in Adult Participants With Relapsed and Refractory Multiple Myeloma

This is a Phase II study to determine the efficacy and safety of PHE885, a BCMA-directed CAR-T cells, manufactured with a new process. CAR-T cells will be investigated as a single

Study number:
NCT05172596
Cohorts:
1
Study phase:
2
Overall status:
Recruiting
Study type:
Targeted therapy

Novartis

Key trial

Study of Efficacy and Safety of NIS793 in Combination With Standard of Care (SOC) Chemotherapy in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) - daNIS-2

The purpose of this study is to evaluate the efficacy and safety of NIS793 in combination with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel and placebo in first-lin

Study number:
NCT04935359
Cohorts:
2
Study phase:
3
Overall status:
Recruiting
Study type:
Targeted therapy, Chemotherapy

Novartis

Key trial

An International Prospective Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With SoC, Versus SoC Alone, in Adult Male Patients With mHSPC

The purpose of this study is to evaluate the efficacy and safety of 177Lu-PSMA-617 in combination with Standard of Care, versus Standard of Care alone, in adult male patients with

Study number:
NCT04720157
Cohorts:
1
Study phase:
3
Overall status:
Recruiting
Study type:
Local/Regional therapies, Chemotherapy

Novartis

Key trial

Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation

This is a phase Ib/II open label study. The escalation part will characterize the safety and tolerability of JDQ443 single agent and JDQ443 in combination with the other study trea

Study number:
NCT04699188
Cohorts:
1
Study phase:
1, 2
Overall status:
Recruiting
Study type:
Targeted therapy, Biomarker

Novartis

Key trial

Safety and Preliminary Efficacy of JBH492 Monotherapy in Patients With CLL and NHL

The purpose of the First-In-Human study is to assess safety, tolerability, pharmacokinetics (PK), immunogenicity and preliminary efficacy of JBH492 as single agent.

Study number:
NCT04240704
Cohorts:
1
Study phase:
1
Overall status:
Recruiting
Study type:
Chemotherapy, Targeted therapy

Novartis

Key trial

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

The purpose of this first in human (FIH) trial is to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and ide

Study number:
NCT03114319
Cohorts:
2
Study phase:
1
Overall status:
Recruiting
Study type:
Targeted therapy, Biomarker